[FEMA-1135-DR]

# Virginia; Amendment to Notice of a Major Disaster Declaration

**AGENCY:** Federal Emergency Management Agency (FEMA).

**ACTION:** Notice.

**SUMMARY:** This notice amends the notice of a major disaster for the Commonwealth of Virginia, (FEMA–1135–DR), dated September 6, 1996, and related determinations.

EFFECTIVE DATE: September 17, 1996. FOR FURTHER INFORMATION CONTACT: Pauline C. Campbell, Response and Recovery Directorate, Federal Emergency Management Agency, Washington, DC 20472, (202) 646–3606. SUPPLEMENTARY INFORMATION: The notice of a major disaster for the Commonwealth of Virginia, is hereby amended to include the following areas among those areas determined to have been adversely affected by the catastrophe declared a major disaster by the President in his declaration of September 6, 1996:

The independent cities of Buena Vista and Emporia and the counties of Amherst, Campbell, and Prince Edward for Public Assistance and Hazard Mitigation (already designated for direct Federal assistance).

Rockbridge County for Public Assistance (already designated for Individual Assistance, Hazard Mitigation, and direct Federal assistance).

Alleghany, Greene, Henry, and Montgomery Counties for Hazard Mitigation (already designated for Individual Assistance and direct Federal assistance)

(Catalog of Federal Domestic Assistance No. 83.516, Disaster Assistance.)

William C. Tidball.

Associate Director, Response and Recovery Directorate.

[FR Doc. 96–25221 Filed 10–1–96; 8:45 am] BILLING CODE 6718–02–P

#### FEDERAL RESERVE SYSTEM

# Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act, including whether the acquisition of the nonbanking company can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices" 1843). Any request for (12 U.S.C. a hearing must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 16, 1996.

A. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. Richey Bancorporation, Inc., and Community First Bancorp, both of Glendive, Montana; to engage de novo through Community First Bancorp, in management consulting services to depository institutions, pursuant to § 225.25(b)(11) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, September 26, 1996.

Jennifer J. Johnson

Deputy Secretary of the Board [FR Doc. 96–25185 Filed 10-1-96; 8:45 am]

### BILLING CODE 6210-01-F

### Notice of Meeting of Consumer Advisory Council

The Consumer Advisory Council will meet on Thursday, October 24, 1996. The meeting, which will be open to public observation, will take place in Terrace Room E of the Martin Building. The meeting is expected to begin at 9:00 am and to continue until 4:00 pm, with a lunch break from 1:00 pm until 2:00 pm. The Martin Building is located on C Street, Northwest, between 20th and 21st Streets in Washington, D.C.

The Council's function is to advise the Board on the exercise of the Board's responsibilities under the Consumer Credit Protection Act and on other matters on which the Board seeks its advice. Time permitting, the Council will discuss the following topics:

Report on the Home Mortgage Loan Closing Paperwork. The Council's Community Affairs and Housing Committee and Consumer Credit Committee will report on their review and assessment of the home mortgage loan closing paperwork process.

CRA Implementation - Large Bank Examination Issues. The Bank Regulation Committee will discuss large-bank examination issues—the lending, investment, and service tests; data collection; and strategic plans—and the ratings system under the Community Reinvestment Act.

Revisions to the Bank Holding Company Act—Streamlining the Application and Notice Process for Regulation Y. The Bank Regulation Committee will discuss the Board's proposed revisions to Regulation Y (Bank Holding Companies), which are intended to improve competitiveness of bank holding companies by eliminating unnecessary regulatory burden and operating restrictions.

Consumer Disclosures on Stored-Value Cards. The Depository and Delivery Systems Committee will report on issues relating to consumer disclosures on stored-value cards.

Dollar Coin. The Depository and Delivery Systems Committee will discuss issues surrounding introduction of a new dollar coin, in substitution for the dollar bill, as would be required by several pending legislative proposals.

Member's Forum. Presentation of individual Council members' views on the economic conditions present within their industries or local economies.

Governor's Report. Report by Federal Reserve Board Member Lawrence B. Lindsey on economic conditions, recent Board initiatives, and issues of concern, with an opportunity for questions from Council members.

Committee Reports. Reports from Council committees on their work for 1996.

Open Forum—Emerging Issues: Internet and Home Banking. (Tentative) Committee reports concerning emerging issues and trends, focusing on the Internet and home banking.

Other matters previously considered by the Council or initiated by Council members also may be discussed.

Persons wishing to submit to the Council their views regarding any of the above topics may do so by sending written statements to Deanna Aday-Keller, Secretary, Consumer Advisory Council, Division of Consumer and Community Affairs, Board of Governors of the Federal Reserve System, Washington, D.C. 20551.

Information with regard to this meeting may be obtained from Ms. Aday-Keller, 202-452-6470. Telecommunications Device for the Deaf (TDD) users may contact Dorothea Thompson, 202-452-3544.

Board of Governors of the Federal Reserve System, September 26, 1996.

William W. Wiles

Secretary of the Board

[FR Doc. 96–25184 Filed 10–1–96; 8:45 am] BILLING CODE 6210–01–F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

# National Institute for Occupational Safety and Health

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the National Institute for Occupational Safety and Health, of the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

*Name:* Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH).

Time and Date: 10 a.m.-5 p.m., October 18, 1996.

Place: NIOSH Research Laboratory, 1095 Willowdale Road, Morgantown, West Virginia 26505.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

*Purpose*: The Board reviews research activities to provide guidance on the quality, timeliness, and efficacy of the Institute's programs.

Matters To Be Discussed: Agenda items include a report from the Director of NIOSH, the Musculoskeletal Program Evaluation, Extramural Activities, National Occupational Research Agenda, Health Hazard Evaluation Program Evaluation, EPA Science Advisory Board Communications, and future activities of the Board.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Bryan D. Hardin, Ph.D., Acting Executive Secretary, BSC, NIOSH, CDC, 1600 Clifton Road, NE, M/S D–35, Atlanta, Georgia 30333, telephone 404/639–3773.

Dated: September 26, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–25169 Filed 10–1–96; 8:45 am]

BILLING CODE 4163-19-M

#### **Food and Drug Administration**

[Docket No. 96N-0340]

Lilly Research Laboratories, et al.; Withdrawal of Approval of 12 New Drug Applications, 8 Abbreviated Antibiotic Applications, and 23 Abbreviated New Drug Applications

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 12 new drug applications (NDA's), 8 abbreviated antibiotic applications (AADA's), and 23 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: October 2, 1996.

### FOR FURTHER INFORMATION CONTACT:

Olivia A. Vieira, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594– 1046.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application no.	Drug	Applicant
NDA 6-470	Calcium Gluceptate	Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285.
NDA 8-826	Chlor-Trimeton Injection	Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033.
NDA 9-585	Cort-Dome (hydrocortisone, cream) Cream, ½%, 1%	Bayer Pharmaceutical, 400 Morgan Ln., West Haven CT 06516–4175.
NDA 11–284	Meprospan (meprobamate) Capsules, 200 milligrams (mg) and 400 mg.	Wallace Laboratories, Half Acre Rd., P.O. Box 1001, Cranbury, NJ 08512–0181.
NDA 16-049	Innovar (fentanyl citrate/droperidol) for Injection	Janssen Pharmaceutica, 1125 Trenton-Harbourton Rd., P.O. Box 200 Titusville, NJ 08560–0200.
NDA 17-589	Solatene (betacarotene) Capsules	Hoffmann-LaRoche Inc., 340 Kingsland St., Nutley, NJ 07110–1199.
NDA 18-669	Niclocide (niclosamide) Tablets	Bayer Pharmaceutical.
NDA 18-806	Indomethacin Capsules, 25 mg and 50 mg	Warner Chilcott Laboratories, 200 Plymouth Rd., Ann Arbor, MI 28105.
NDA 18-830	Tambocor (flecainide acetate) 50, 100, 150 and 200 mg Tablets.	3M Pharmaceuticals, 3M Center, Bldg. 270–3A–01, St. Paul, MN 55144–1000.
NDA 19-329	Sodium Chloride Injection 23.4%	Fujisawa USA, Inc., Parkway North Center, Three Parkway North, Deerfield, IL 60015–2548.
NDA 50-550	Moxan (moxalactam disodium)	Lilly Research Laboratories.
NDA 50-565	Coatin (amdinocillin)	Hoffman-LaRoche, Inc.
AADA 60-107		Lilly Research Laboratories.